Exp Clin Transplant. 2026 Jul;24(Suppl 2):6-9. doi: 10.6002/ect.MESOT2025.L22.
ABSTRACT
Kidney transplantation is the definitive treatment for end-stage renal disease, offering substantial improvements in survival and quality of life. However, the lifelong immunosuppression required to maintain graft function predisposes recipients to a variety of posttransplant malignancies, which can cause morbidity and mortality. This report aimed to synthesize the current understanding of the epidemiology, risk factors, and clinical outcomes associated with posttransplant malignancies in kidney transplant recipients. Current understanding was drawn from review of international registries such as the Scientific Registry of Transplant Recipients and the Australia and New Zealand Dialysis and Transplant Registry, as well as landmark studies and clinical guidelines in the field of transplant oncology. The analysis showed that cancer incidence in kidney transplant recipients is 2 to 3 times higher than in the age-matched general population. Skin cancers, particularly nonmelanoma types, and posttransplant lymphoproliferative disorder are the most frequently observed malignancies. The pathogenesis is multifactorial, with intensity and duration of immunosuppression being the most important risk factor. Other critical factors include viral infections (eg, Epstein-Barr virus, human papillomavirus, BK virus), recipient age, and history of prior cancer. Some newer immunosuppressive agents, like mammalian target of rapamycin inhibitors, have shown promise in reducing the incidence of certain cancers, but their universal application is not supported by current evidence. Malignancy stands as a formidable challenge in the long-term management of kidney transplant recipients, second only to cardiovascular disease as a cause of death. A successful strategy to mitigate this risk requires a delicate balance between preventing graft rejection and minimizing the oncogenic potential of immunosuppressive therapy. Vigilant screening, individualized treatment regimens, and robust preventive measures are essential to improving outcomes and reducing the cancer burden in this vulnerable population.
PMID:42538649 | DOI:10.6002/ect.MESOT2025.L22